Heart Failure Clinical Trial
American Registry of Ambulatory or Acute Decompensated Heart Failure
Summary
The purpose of this study is to better characterize and understand the population of patients with ambulatory or acutely decompensated heart failure in the American continent, getting to know their sociodemographic, clinical and paraclinical characteristics
Full Description
An observational, prospective and multicenter study in which ambulatory patients with a confirmed diagnosis of heart failure and those admitted to the hospitalization service due to an episode of acutely decompensated heart failure will be invited to participate in order to better characterize this population
Participants who meet the eligibility criteria will be evaluated at the moment of recruitment. Follow-ups will be performed at 1, 6 and 12 months after the initial registry for hospitalized patients. For ambulatory patients follow-up will only be performed at 12 months. These initial evaluations and subsequents follow-ups will be carried out using a standardized form for the collection of hospital and outpatient data through an electronic platform
The purpose of this study is to know sociodemographic, clinical (clinical presentation, hemodynamic profiles, in-hospital and outpatient management, re-hospitalization rate, proportion of mortality, cumulative survival and heart failure readmission-free survival) and paraclinical characteristics of this population
Eligibility Criteria
Inclusion Criteria:
Patient aged 18 years or older and one of the following:
Hospitalized patient with admission diagnosis of acutely decompensated heart failure or
Outpatient with confirmed diagnosis (main or complementary) of heart failure
Exclusion Criteria:
Hospitalized patient with principal diagnosis of another cardiovascular / non-cardiovascular pathology and who develops an acute decompensation of heart failure during hospitalization.
Patient on heart transplant waiting list
Patient who has implanted or is in process of implanting a long-term ventricular assist device (eg, Heart Mate II, Heart Mate III) as a target therapy or bridge therapy to other therapies
Patient in whom palliative management has been previously defined for his/her cardiac condition (i.e. Heart failure) or for another associated medical condition (cancer, chronic obstructive pulmonary disease (COPD), etc.)
Patient who is discharged or referred to another institution within 48 hours of hospital stay
Inability to comply with programmed follow-ups (telephone or in person) due to social, personal or other conditions considered by the principal investigator
Life expectancy less than 6 months given a condition other than heart failure (Cancer, COPD, etc.)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 44 Locations for this study
Manhasset New York, 11030, United States More Info
Principal Investigator
Dallas Texas, 75390, United States More Info
Principal Investigator
Quilmes Buenos Aires, 1878, Argentina More Info
Principal Investigator
Quilmes Buenos Aires, , Argentina More Info
Principal Investigator
Santa Rosa La Pampa, 6300, Argentina More Info
Principal Investigator
Rosario Santa Fé, 2000, Argentina More Info
Principal Investigator
Buenos Aires , 1617, Argentina More Info
Principal Investigator
Corrientes , 3400, Argentina More Info
Principal Investigator
Córdoba , 5000, Argentina More Info
Principal Investigator
Córdoba , , Argentina More Info
Principal Investigator
San Juan , 5400, Argentina More Info
Principal Investigator
San Juan , , Argentina More Info
Principal Investigator
San Juan , , Argentina More Info
Principal Investigator
San Luis , , Argentina More Info
Principal Investigator
Santa Cruz de la Sierra Santa Cruz, , Bolivia More Info
Principal Investigator
Santa Cruz de la Sierra , , Bolivia More Info
Contact
Principal Investigator
Medellín Antioquia, 05000, Colombia More Info
Principal Investigator
Barranquilla Atlantico, 08000, Colombia More Info
Principal Investigator
Manizales Caldas, 17000, Colombia More Info
Principal Investigator
Florencia Caquetá, 18000, Colombia More Info
Principal Investigator
Bogotá Cundinamarca, 11085, Colombia More Info
Principal Investigator
Bogotá Cundinamarca, 11091, Colombia More Info
Principal Investigator
Bogotá Cundinamarca, 11091, Colombia More Info
Principal Investigator
Montería Córdoba, , Colombia More Info
Principal Investigator
Santa Marta Magdalena, 47000, Colombia More Info
Principal Investigator
Pereira Risaralda, 66000, Colombia More Info
Principal Investigator
Floridablanca Santander, , Colombia More Info
Principal Investigator
Heredia , 40103, Costa Rica More Info
Principal Investigator
San José , 10102, Costa Rica More Info
Principal Investigator
San José , 10102, Costa Rica More Info
Principal Investigator
La Habana Departamento Occidental, 10000, Cuba More Info
Principal Investigator
Santiago De Los Caballeros Santiago, 51000, Dominican Republic More Info
Principal Investigator
Santiago De Los Caballeros Santiago, 51000, Dominican Republic More Info
Principal Investigator
San Francisco de Macoris , , Dominican Republic More Info
Principal Investigator
Santiago De Los Caballeros , , Dominican Republic More Info
Contact
Principal Investigator
Guayaquil Guayas, 09010, Ecuador More Info
Principal Investigator
Guayaquil Guayas, 09051, Ecuador More Info
Principal Investigator
Manta Manabí, EC130, Ecuador More Info
Principal Investigator
Portoviejo Manabí, EC130, Ecuador More Info
Principal Investigator
Quito Pichincha, 17052, Ecuador More Info
Principal Investigator
Cuenca , , Ecuador More Info
Principal Investigator
San Salvador , , El Salvador More Info
Principal Investigator
San Salvador , , El Salvador More Info
Principal Investigator
Chimaltenango , 04001, Guatemala More Info
Principal Investigator
Ciudad de Guatemala , 1001 , Guatemala More Info
Principal Investigator
Ciudad de Guatemala , 1001 , Guatemala More Info
Principal Investigator
Quetzaltenango , 09001, Guatemala More Info
Principal Investigator
Zacapa , 19001, Guatemala More Info
Principal Investigator
Tegucigalpa Francisco Morazán, 11101, Honduras More Info
Principal Investigator
Tegucigalpa Francisco Morazán, 11101, Honduras More Info
Principal Investigator
Kingston , , Jamaica More Info
Principal Investigator
Monterrey Nuevo León, 64000, Mexico More Info
Principal Investigator
Aguascalientes , 20000, Mexico More Info
Principal Investigator
Ciudad de México , 01000, Mexico More Info
Principal Investigator
Ciudad de México , 14080, Mexico More Info
Principal Investigator
Ciudad de México , 14080, Mexico More Info
Principal Investigator
Monterrey , , Mexico More Info
Principal Investigator
Managua , , Nicaragua More Info
Principal Investigator
Ciudad de Panamá , , Panama More Info
Principal Investigator
Itauguá Central, 2740, Paraguay More Info
Principal Investigator
Asunción , 1001-, Paraguay More Info
Principal Investigator
Asunción , 1001-, Paraguay More Info
Principal Investigator
Asunción , , Paraguay More Info
Principal Investigator
Concepción , , Paraguay More Info
Principal Investigator
San Lorenzo , , Paraguay More Info
Principal Investigator
Chimbote Áncash, , Peru More Info
Principal Investigator
Paramaribo , , Suriname More Info
Principal Investigator
Montevideo , 11000, Uruguay More Info
Principal Investigator
Puerto Ordaz Bolívar, 8050, Venezuela More Info
Principal Investigator
Puerto Cabello Carabobo, , Venezuela More Info
Principal Investigator
Valencia Carabobo, 2001, Venezuela More Info
Principal Investigator
Barquisimeto Lara, 3001, Venezuela More Info
Principal Investigator
Cumaná Sucre, 6101, Venezuela More Info
Principal Investigator
Anzoátegui , , Venezuela More Info
Principal Investigator
Mérida , 5101, Venezuela More Info
Principal Investigator
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.